Vertex Expands Cystic Fibrosis Reach As Kidney Drug Nears FDA Decision [Yahoo! Finance]
Vertex Pharmaceuticals Incorporated (VRTX)
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.vrtx.com
Company Research
Source: Yahoo! Finance
Vertex Pharmaceuticals received FDA approval for expanded use of its cystic fibrosis therapies, increasing the number of eligible patients. The company also completed a priority Biologics License Application submission to the FDA for povetacicept for IgA nephropathy. These regulatory milestones relate directly to areas of high unmet medical need in respiratory and kidney disease. Vertex Pharmaceuticals (NasdaqGS:VRTX) is drawing attention after securing broader FDA approvals for its cystic fibrosis portfolio and advancing povetacicept into priority review. The stock last closed at $446.54, with a 3 year return of 42.0% and a 5 year return of 107.4%. This provides context for how the market has previously reacted to the company's drug pipeline and commercial progress. For investors, an important consideration is how these regulatory steps may relate to patient uptake and revenue over time in cystic fibrosis and IgA nephropathy. The expanded cystic fibrosis eligibility and pote
Show less
Read more
Impact Snapshot
Event Time:
VRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRTX alerts
High impacting Vertex Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
VRTX
News
- Vertex Pharma wins FDA label expansion for cystic fibrosis therapies [Seeking Alpha]Seeking Alpha
- Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States [Yahoo! Finance]Yahoo! Finance
- Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United StatesBusiness Wire
- Wells Fargo Raises Vertex Pharmaceuticals (VRTX) Price Target to $550 [Yahoo! Finance]Yahoo! Finance
- 2 Large-Cap Stocks with Exciting Potential and 1 Facing Headwinds [Yahoo! Finance]Yahoo! Finance
VRTX
Earnings
- 2/12/26 - Beat
VRTX
Sec Filings
- 4/1/26 - Form 144
- 3/31/26 - Form 4
- 3/31/26 - Form 8-K
- VRTX's page on the SEC website